Post Marketing Surveillance of Remicade in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Patients.

Trial Profile

Post Marketing Surveillance of Remicade in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Oct 2013

At a glance

  • Drugs Infliximab (Primary)
  • Indications Ankylosing spondylitis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Jun 2012 Actual patient numbers amended from 125 to 1055 as reported by ClinicalTrials.gov.
    • 20 Jun 2012 Actual end date changed from May 2011 to Apr 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top